Caribou Biosciences closes after failing to fund pivotal CAR-T trial

Key points

• Caribou Biosciences announced it is halting all clinical development and implementing a substantial workforce reduction, expected to be complete by the end of 2026.
• The company failed to raise funds for a Phase 3 trial of vispa-cel, an off-the-shelf CAR-T therapy for advanced B-cell non-Hodgkin lymphoma, despite reaching an agreement with the FDA on the trial design.
• Caribou had $113.8 million in cash as of June 30, 2026, but CEO Rachel Haurwitz stated that the current financing environment for allogeneic therapies made securing necessary capital impossible.
• The company is exploring strategic alternatives, including a potential merger, acquisition, or sale of assets, hoping other organizations can advance its technology.
• Vispa-cel demonstrated median progression-free survival comparable to Bristol Myers Squibb’s Breyanzi and Kite Pharma’s Yescarta in Phase 1 trials, marking the first allogeneic CAR-T to match autologous efficacy.

Background

Caribou Biosciences, founded in 2011 from the lab of CRISPR pioneer Jennifer Doudna, focused on allogeneic (donor-derived) CAR-T therapies to avoid the lengthy manufacturing times associated with patient-specific treatments. Recent industry trends have shifted investor and developer interest toward in vivo gene editing, where cells are modified inside the patient’s body, reducing the need for external cell extraction and manufacturing. This shift has created a challenging funding climate for traditional allogeneic CAR-T developers, as major pharmaceutical companies like Eli Lilly and Johnson & Johnson have entered the in vivo arena.

How outlets are covering it

STAT reported that Caribou successfully finalized the design of a Phase 3 trial with the FDA but could not raise the money to execute it, framing the closure as a funding failure rather than a scientific one. Fierce Biotech emphasized the broader industry context, noting that the rise of in vivo therapies has created a 'nuclear winter' for allogeneic CAR-T funding, with even established players like Cellectis pivoting to in vivo approaches. Fierce also highlighted that Caribou’s vispa-cel matched the efficacy of leading autologous therapies in early trials, suggesting the science was sound but the business model was unviable in the current market. FirstWord Pharma’s content was inaccessible due to a JavaScript error and provided no additional information.

Why it matters

The closure of Caribou Biosciences highlights the intense capital constraints facing allogeneic CAR-T developers as the industry pivots toward in vivo gene editing. It underscores the risk that even promising therapies with proven efficacy can fail to reach the market if they cannot secure funding in a shifting investment landscape. The company’s potential sale or merger could allow its technology to continue development under a new owner, potentially preserving access to off-the-shelf CAR-T options for lymphoma and myeloma patients.

What to watch

Caribou Biosciences will complete its workforce reduction in the fourth quarter of 2026 while its board explores strategic alternatives, including a sale or merger. The company’s assets, including its vispa-cel and CB-011 programs, may be acquired by another organization with the resources to advance them. Investors and the biotech industry will continue to monitor the shift toward in vivo therapies and the fate of remaining allogeneic CAR-T developers.